Midostaurin as a Novel Drug for the Therapy of FLT3 Mutation-positive Acute Myeloid Leukaemia / 中国药师
China Pharmacist
;
(12): 490-492, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-705567
ABSTRACT
Midostaurin is an orally administered inhibitor of multiple tyrosine kinase receptors developed by Novartis Pharmaceuti-cals. In May 2017,it was approved in the USA for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukaemia (AML). Its pharmacokinetics,pharmacodynamics,clinical trials,adverse effects and drug interactions were introduced in the paper.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
China Pharmacist
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS